Highlights

  • Immutep has redirected planned efti development towards selected head and neck cancer and soft tissue sarcoma settings.
  • The Phase III TACTI-004 lung cancer trial was discontinued after an interim futility assessment.
  • A manufacturing-related investigation identified differences between efti batches produced at different scales.
  • The company reported A$68.87 million in cash, cash equivalents and term deposits at 30 June 2026.
  • The clinical pipeline also includes IMP761, a LAG-3 agonist antibody investigated for autoimmune diseases.

Immutep Limited (ASX:IMM) develops immunotherapies that target the LAG-3 immune regulatory pathway for cancer and autoimmune disease applications. During 2026, its development priorities changed following the discontinuation of a major lung cancer study, while the company continued evaluating eftilagimod alfa (efti), its lead oncology candidate, and IMP761. The revised clinical strategy places greater emphasis on selected patient populations and Manufacturing consistency.

TACTI-004 Outcome Reshapes Clinical Priorities

In March 2026, an independent monitoring committee recommended stopping the Phase III TACTI-004 study in first-line non-small cell lung cancer after a planned interim futility analysis. Immutep (ASX:IMM) subsequently ceased enrolment and began winding down the study. The outcome does not establish efficacy for the indication and led the company to review clinical, operational, pharmacological and manufacturing factors.

In a September 11, 2026 update, Immutep said its investigation had identified subtle analytical differences between efti manufactured at 200 L scale and 2,000 L scale, including structural differences relevant to immune activation. The company described these findings as potentially relevant to the unexpected trial outcome, rather than a proven explanation. A new 200 L manufacturing run was contracted.

Efti Focus Moves to Selected Cancer Settings

Immutep (ASX:IMM) outlined a narrower approach for potential registration-directed development of efti. It identified head and neck squamous cell carcinoma with negative PD-L1 expression (CPS below 1) and the neoadjuvant soft tissue sarcoma setting as intended areas of focus. Preparations for further studies had begun, with starts targeted for the second half of calendar 2027, subject to study design, regulatory dialogue, manufacturing, partnerships and resources.

The company received US Orphan Drug designation for efti in soft tissue sarcoma in April 2026 and has also referred to Fast Track Designation for its head and neck cancer programme. Such designations do not constitute Marketing approval. For ASX:IMM, later-stage development remains contingent on further clinical evidence and regulatory requirements.

Other Clinical Data and FY26 Funding

In July 2026, Immutep reported a mature median overall survival of 30.9 months in the 51 evaluable patients in the investigator-initiated INSIGHT-003 first-line lung cancer study. These results came from a different trial design and do not reverse the TACTI-004 outcome. ASX:IMM also reported that its IMP761 first-in-human programme had met its primary safety endpoint and shown pharmacodynamic activity.

At 30 June 2026, Immutep (ASX:IMM) held A$68.87 million in cash, cash equivalents and term deposits. Its July Quarterly Report stated that cost-reduction measures were underway, with a projected funding runway into the first half of calendar 2028. This projection is subject to changes in spending, clinical plans and other funding requirements.

Clinical and Operational Risks

The next phase of development depends on manufacturing comparability, trial design, patient recruitment and regulatory engagement. Efti still requires adequate evidence of safety and efficacy in the populations selected for further study. Funding needs may also change as projects advance. The TACTI-004 discontinuation illustrates how interim clinical assessments can materially change trial programmes.

Key Insights

Immutep (ASX:IMM) enters its next development phase with a more focused efti programme, an ongoing manufacturing investigation and a separate autoimmune immunotherapy candidate. Its reported FY26 Liquidity provides context for planned activities, while the timing and design of future studies remain conditional. Clinical outcomes, reproducible manufacturing and regulatory decisions will determine subsequent programme milestones.